Institution

University Medical Center Hamburg-Eppendorf

Hamburg, GermanyWebsite

Also known as: Universitätsklinikum Hamburg-Eppendorf · UKE

462running trials
170closed trials
2researchers
82,990publications (OpenAlex)

Researchers

Marcel S Woo
Nicolaus Kröger

Running trials

Not yet recruiting
Spontaneous Coronary Artery Dissection - AntipLatelet Therapy Intensity in Guided coNservative Management (SCAD-ALIGN) Trial
NCT07683923· Phase 4· Universitätsklinikum Hamburg-Eppendorf· Source
Not yet recruiting
A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination with Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants with First-Line Metastatic Pancreatic Ductal Adenocarcinoma
2025-522563-15-00· Phase 2/3· AbbVie Deutschland GmbH & Co. KG· Source
Not yet recruiting
Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma
NCT07291102· Phase 3· Nationwide Children's Hospital· Source
Not yet recruiting
Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis
NCT07441408· Phase 3· Bristol-Myers Squibb· Source
Not yet recruiting
A Study of Mirdametinib in Infants and Toddlers With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas
NCT07850635· Phase 1· SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany· Source
Not yet recruiting
Real-World Data Collection of GORE Devices Used In the Endovascular Treatment of Aortic Aneurysms Which Incorporate Visceral Arteries.
NCT07480395· W.L.Gore & Associates· Source
Not yet recruiting
Post-intervention dual antiplatelet therapy for mild stroke
2026-525681-22-00· Phase 3· Technische Universitaet Dresden· Source
Not yet recruiting
Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma
NCT07600151· Phase 1/2· Universitätsklinikum Hamburg-Eppendorf· Source
Recruiting
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants with Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
2024-518365-10-00· Phase 3· F. Hoffmann-La Roche AG· Source
Not yet recruiting
A study to investigate safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis (stage F4 fibrosis) due to MASH (NEBULA-2)
2026-525757-37-00· Phase 3· Glaxosmithkline Research & Development Limited· Source
Not yet recruiting
A pivotal clinical study to investigate the safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis due to Metabolic dysfunction-associated steatohepatitis (MASH)
2026-525755-82-00· Phase 3· Glaxosmithkline Research & Development Limited· Source
Recruiting
Cevostamab in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy in Participants With Previously Treated Multiple Myeloma
NCT07825064· Phase 2· Hoffmann-La Roche· Source
Not yet recruiting
A Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic Dermatitis
NCT07873801· Phase 3· Almirall, S.A.· Source
Not yet recruiting
A trial to learn how well AZD0120 works and about its safety in adults with transplant eligible newly diagnosed multiple myeloma.
2026-525367-40-00· Phase 3· AstraZeneca AB· Source
Not yet recruiting
Study of the safety and efficacy of asciminib in pediatric and young adult participants with r/r Ph+ or ABL-class Ph-like ALL
2025-522019-40-00· Phase 1/2· Novartis Pharma AG· Source
Not yet recruiting
Balloon- Versus Self-Expanding Intraannular TAVI in Small Aortic Annuli
NCT07794306· Universitätsklinikum Hamburg-Eppendorf· Source
Recruiting
A Phase III, Open-Label, Randomised, Multicentre, Global Study of Adjuvant Datopotamab Deruxtecan in Combination With Rilvegostomig in Participants With High-risk Muscle Invasive Urothelial Carcinoma.
2025-525030-57-00· Phase 3· AstraZeneca AB· Source
Not yet recruiting
Continuous or Intermittent Cetuximab Plus FOLFIRI as First-line Treatment in RAS/BRAF Wild-type mCRC Patients
NCT07004413· Phase 3· Charite University, Berlin, Germany· Source
Enrolling by invitation
International Multicenter Outcomes of Transcatheter Pulmonary Flow Restrictors in Congenital and Acquired Heart Disease
NCT07791069· Fondation Hôpital Saint-Joseph· Source
Recruiting
Reduction of SystemiC Inflammation After Ischemic Stroke by Intravenous DNase Administration (ReSCInD)
NCT05880524· Phase 2· Ludwig-Maximilians - University of Munich· Source
Not yet recruiting
A study to Evaluate the Efficacy and Safety of ENV-294 in Adult Participants with Moderate-to-Severe Atopic Dermatitis
2026-526184-38-00· Phase 2· Enveda Therapeutics Inc.· Source
Recruiting
AI-Based Tools for Stroke Diagnosis, Treatment and Outcome Prediction: a Multicentre Prospective Observational Study
NCT07924371· Hospital Universitari Vall d'Hebron Research Institute· Source
Recruiting
Efanesoctocog alfa treatment in patients with congenital hemophilia A suffering from inflammation of joint lining
2025-523896-44-00· Phase 3· GWT-Tud GmbH· Source
Recruiting
Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)
NCT07711002· Phase 3· AstraZeneca· Source
Recruiting
A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia
NCT07623200· Phase 3· Incyte Corporation· Source
Recruiting
A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D–Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)
2025-525009-18-00· Phase 3· Incyte Corp.· Source
Recruiting
A Phase IIb Study to Evaluate AZD8965 in Participants with Idiopathic Pulmonary Fibrosis (IPF)
2025-525016-41-00· Phase 2· AstraZeneca AB· Source
Recruiting
A trial to learn how well AZD0120 works and how safe it is in people with relapsed or refractory multiple myeloma.
2025-523285-25-00· Phase 3· AstraZeneca AB· Source
Recruiting
A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC
NCT07807163· Phase 2· Bicara Therapeutics· Source
Not yet recruiting
NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer
NCT07178730· Phase 3· Women's Cancer Study Group GmbH· Source
Recruiting
Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy
2025-524335-39-00· Phase 3· Gilead Sciences Inc.· Source
Recruiting
Maintaining Intraoperative Mean Arterial Pressure at 85 mmHg or Higher to Reduce Postoperative Delirium in Older Patients With Arterial Hypertension Having Non-cardiac Surgery
NCT07713121· Universitätsklinikum Hamburg-Eppendorf· Source
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax (ABBV-453) Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
2025-525105-20-00· Phase 1/2· AbbVie Deutschland GmbH & Co. KG· Source
Recruiting
A study to evaluate the efficacy of oxaliplatin- or gemcitabine-based chemotherapy after allocation by standard criteria or by genetic markers in patients with resected pancreatic carcinoma
NCT05314998· Phase 3· Universitaetsklinikum Heidelberg AöR· Source
Active, not recruiting
A prospective, multicentre, randomised, double-dummy, double-blind, placebo-controlled 3-way Phase III study to investigate the efficacy and safety of two dexamfetamine sulfate formulations in adults with ADHD - DEXINA -
2022-502903-31-00· Phase 3· Medice Arzneimittel Puetter GmbH & Co. KG· Source
Recruiting
A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer
NCT07673887· Phase 3· Astellas Pharma Global Development, Inc.· Source
Not yet recruiting
Master Study Protocol for the Cohort of the Specialist Network Stroke (SN Stroke)(Stroke-CORE)
NCT07553650· Charite University, Berlin, Germany· Source
Recruiting
Registry for Duchenne and Becker Muscular Dystrophy
NCT07402122· Dr. Andreas Ziegler· Source
Recruiting
An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS
NCT07665437· Phase 3· Novartis Pharmaceuticals· Source
Recruiting
Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease
NCT07318610· Phase 3· Regeneron Pharmaceuticals· Source
Recruiting
A Study to Find an Efficacious and Safe Dose of CHF10067 (Zampilimab) in Participants With Idiopathic Pulmonary Fibrosis
NCT07516951· Phase 2· Chiesi Farmaceutici S.p.A.· Source
Recruiting
A Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma
2025-523815-12-00· Phase 3· Janssen Cilag International· Source
Recruiting
Evaluation of an Exercise Intervention During Intensive Medical Treatment in Pediatric Oncology.
NCT07647471· Universität Duisburg-Essen· Source
Not yet recruiting
GMMG-HD11/DSMM XXI/64007957MMY3010
NCT07671287· Phase 3· University of Heidelberg Medical Center· Source
Recruiting
A randomized double-masked, multicenter, 3 arm pivotal Phase 2/3 study to evaluate the efficacy and safety of intravitreal (IVT) EYE201/MK-8748 in participants with neovascular age-related macular degeneration (NVAMD)
2025-524575-22-00· Phase 2/3· Eyebiotech Limited· Source
Recruiting
Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF)
NCT07284602· Phase 3· PureTech· Source
Recruiting
Revumenib Treatment in Combination with FLA Chemotherapy in Paediatric Refractory/Relapsed KMT2A-r, NUP98-r or NPM1-mut Acute Myeloid Leukemia (AML)
2025-521390-14-00· Phase 2· Pediatric Research International GmbH· Source
Recruiting
Dehydroepiandrosterone (DHEA) as Augmentation of Standard Antidepressants in Treatment-resistant Depression.
NCT07843927· Phase 3· Charite University, Berlin, Germany· Source
Recruiting
A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
NCT07554339· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
Study to evaluate the safety and efficacy of asciminib in pediatric participants with chronic myeloid leukemia.
2025-522138-29-00· Phase 2· Novartis Pharma AG· Source

Showing 50 of 462.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Childhood cancers44 recruiting
Multiple myeloma25 recruiting
Stroke17 recruiting
Acute lymphoblastic leukaemia14 recruiting
Prostate cancer13 recruiting
Acute myeloid leukaemia12 recruiting
Melanoma12 recruiting
Atrial fibrillation9 recruiting
High blood pressure9 recruiting
Lung cancer9 recruiting
Colorectal cancer8 recruiting
Heart failure8 recruiting
Macular degeneration7 recruiting
Ovarian cancer7 recruiting
Sarcoma7 recruiting
Bladder cancer6 recruiting
Coronary artery disease6 recruiting
Haemophilia6 recruiting
Multiple sclerosis6 recruiting
Pancreatic cancer6 recruiting
Chronic kidney disease5 recruiting
Idiopathic pulmonary fibrosis5 recruiting
Liver and biliary tract cancer5 recruiting
Myeloproliferative neoplasms5 recruiting
Parkinson disease5 recruiting
Pulmonary arterial hypertension5 recruiting
Atopic dermatitis (eczema)4 recruiting
Chronic lymphocytic leukaemia4 recruiting
Endometrial cancer4 recruiting
Follicular lymphoma4 recruiting
Gastric and oesophageal cancer4 recruiting
Hodgkin lymphoma4 recruiting
Obesity4 recruiting
Peripheral artery disease4 recruiting
Aortic stenosis3 recruiting
Brain aneurysm3 recruiting
Cervical cancer3 recruiting
Chronic myeloid leukaemia3 recruiting
Diffuse large B-cell lymphoma3 recruiting
Duchenne muscular dystrophy3 recruiting
Fatty liver disease (MASLD/MASH)3 recruiting
Head and neck cancer3 recruiting
Kidney cancer3 recruiting
Mantle cell lymphoma3 recruiting
Metastatic breast cancer3 recruiting
Myelodysplastic syndromes3 recruiting
Aortic aneurysm2 recruiting
Autism2 recruiting
Coeliac disease2 recruiting
Hidradenitis suppurativa2 recruiting
HIV2 recruiting
IgA nephropathy2 recruiting
Liver cirrhosis2 recruiting
Myasthenia gravis2 recruiting
Neuroblastoma2 recruiting
Psoriasis2 recruiting
Alzheimer disease1 recruiting
CIDP (chronic inflammatory demyelinating polyneuropathy)1 recruiting
Congenital heart disease1 recruiting
COPD1 recruiting
Crohn's disease1 recruiting
Depression1 recruiting
Dermatomyositis and polymyositis (myositis)1 recruiting
Dystonia1 recruiting
Eosinophilic oesophagitis1 recruiting
Glioblastoma1 recruiting
Hepatitis B1 recruiting
Huntington's disease1 recruiting
Hyperparathyroidism1 recruiting
Lupus (SLE)1 recruiting
Myocarditis1 recruiting
Nephrotic syndrome1 recruiting
Neuroendocrine tumours1 recruiting
Neurofibromatosis type 11 recruiting
Obstructive sleep apnoea1 recruiting
Polycystic kidney disease1 recruiting
Rheumatoid arthritis1 recruiting
Schizophrenia1 recruiting
Sickle cell disease1 recruiting
Systemic sclerosis (scleroderma)1 recruiting
Triple-negative breast cancer1 recruiting
Tuberculosis1 recruiting
Type 2 diabetes1 recruiting
Ulcerative colitis1 recruiting
Vascular dementia1 recruiting
Vitiligo1 recruiting

Closed trials

Completed
A multi-part, adaptive, Phase 1, first time in human study in healthy participants and participants with atopic dermatitis (AD) to assess the safety, tolerability, pharmacokinetics (PK) of single ascending (SAD), multiple ascending doses (MAD) and selected dose of SYX-5219 (AD Participants)
2025-522216-17-00· Phase 1· Sitryx Therapeutics Limited· Source
Active, not recruiting
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma
NCT07288203· Phase 2· Iovance Biotherapeutics, Inc.· Source
Completed
Testing of an Interface for Synchronizing tACS-DBS With a Phase-locked-loop
NCT07139093· Universitätsklinikum Hamburg-Eppendorf· Source
Completed
Pulsed Field or Cryoballoon Pulmonary Vein Isolation for Atrial Fibrillation in Heart Failure
NCT07181291· St. Josefs-Hospital Wiesbaden GmbH· Source
Completed
A Study to Test How BI 3031185 is Tolerated by People With Borderline Personality Disorder or Attention-deficit/Hyperactivity Disorder
NCT07001475· Phase 1· Boehringer Ingelheim· Source
Completed
Chronical Illness-related Limitations of the Ability to Cope With Rising Temperatures, Third Wave
NCT06890208· Universitätsklinikum Hamburg-Eppendorf· Source
Completed
Surgical or radiotherapeutic intervention concerning large singular stable to progressive metastases in patients with BRAFV600-mutated melanoma receiving treatment with Encorafenib + Binimetinib
2024-516073-74-00· Phase 4· SRH Wald-Klinikum Gera GmbH· Source
Active, not recruiting
A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer
NCT06521567· Phase 1/2· GlaxoSmithKline· Source
Active, not recruiting
A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis
NCT06744920· Phase 3· Novartis Pharmaceuticals· Source
Completed
Bifocal Transcranial Alternating Current Stimulation Targeting the Frontoparietal Network in Stroke Patients
NCT06809959· Universitätsklinikum Hamburg-Eppendorf· Source
Completed
A study to find a suitable dose of BI 765883 and to test whether it helps people with advanced pancreatic cancer when taken alone or together with chemotherapy
2023-508998-85-00· Phase 1· Boehringer Ingelheim International GmbH· Source
Active, not recruiting
A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT06291220· Phase 1· AbbVie· Source
Completed
A study to evaluate the safety and efficacy of mebendazole in combination with low-dose Ara-C in elderly patients with relapsed/refractory acute myeloid leukemia (MAIL)
2024-518363-36-00· Phase 2· University Medical Center Hamburg-Eppendorf· Source
Completed
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024)
NCT06664801· Phase 2· Merck Sharp & Dohme LLC· Source
Completed
A study to evaluate the efficacy and safety of subcutaneous sonelokimab compared with placebo in adult participants with moderate to severe hidradenitis suppurativa
2024-511363-28-00· Phase 3· MoonLake Immunotherapeutics AG· Source
Completed
Cerebellar Transcranial Direct Current Stimulation (tDCS) in Patients With Isolated Cervical Dystonia (CD)
NCT07014384· Universitätsklinikum Hamburg-Eppendorf· Source
Completed
A study to test whether BI 1839100 improves cough in people with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis
2023-510249-79-00· Phase 2· Boehringer Ingelheim International GmbH· Source
Completed
Best End-Expiratory and Driving-pressure for Individualized Flow Controlled Ventilation in Patients With COPD
NCT05812365· Universitätsklinikum Hamburg-Eppendorf· Source
Completed
Peptide-coupled Red Blood Cells for the Treatment of Multiple Sclerosis
NCT06430671· Phase 1· Cellerys AG· Source
Completed
A Study designed to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab administered in participants with PD-L1 ≥ 1% TC Stage IIB, IIIA, or select IIIB (T3N2 only) NSCLC following resection and adjuvant platinum-based chemotherapy
2023-506696-10-00· Phase 3· F. Hoffmann-La Roche AG· Source
Completed
A Real-world Study in Participants With Smoldering Multiple Myeloma
NCT06472778· Janssen-Cilag Ltd.· Source
Completed
Chronical Illness-related Limitations of the Ability to Cope with Rising Temperatures: an Observational Study, 2nd Wave
NCT06407154· Universitätsklinikum Hamburg-Eppendorf· Source
Active, not recruiting
Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma
NCT06216158· Phase 3· University of Heidelberg Medical Center· Source
Active, not recruiting
A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis
NCT06257875· Phase 2· AbbVie· Source
Completed
A Trial to Investigate TransCon TLR7/8 Agonist in Combination with Pembrolizumab, TransCon TLR7/8 Agonist in Combination with TransCon IL-2 β/γ, or Pembrolizumab Monotherapy as Neoadjuvant Therapy in Participants with Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)
2023-506092-10-00· Phase 2· Ascendis Pharma Oncology Division A/S· Source
Completed
Development and EValuation of an Online Intervention to Reduce Self-Stigma in People With Visible Chronic Skin disEases
NCT06324695· Universitätsklinikum Hamburg-Eppendorf· Source
Completed
A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity
NCT06104124· Phase 3· Amgen· Source
Terminated
Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment
NCT05999968· Phase 1· Eli Lilly and Company· Source
Completed
Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)
NCT05934526· Phase 3· GB002, Inc.· Source
Recruiting
BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT
NCT06059638· Orchestra BioMed, Inc· Source
Completed
CA-4948-104: A Ph1 Study of Emavusertib in AML CR MRD+ Patients Currently Receiving Azacitidine and Venetoclax
2023-505828-58-00· Phase 1· Curis Inc.· Source
Completed
The PEERLESS II Study
NCT06055920· Inari Medical· Source
Completed
Radiotherapy plus xevinapant or placebo in older patients with locally advanced head and neck cancer
NCT05724602· Phase 2· European Organisation For Research And Treatment Of Cancer· Source
Completed
Safety, tolerability, and efficacy of ACOU085 for prevention of hearing loss in testicular cancer patients receiving cisplatin
NCT06521190· Phase 2· Acousia Therapeutics GmbH· Source
Completed
An Observational Study to Validate the Cumulative Life Course Impairment (CLCI) Instrument (DermCLCI-p) in Adult Participants With Moderate to Severe Chronic Plaque Psoriasis (PsO)
NCT05959070· AbbVie· Source
Completed
A Phase 3b, Open-label Study to Evaluate the Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis
2023-505558-16-00· Phase 3· Almirall S.A.· Source
Completed
A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
NCT06046729· Phase 2· Eli Lilly and Company· Source
Completed
A Phase 3, Double-blind Maintenance Study Assessing Rocatinlimab in Moderate-to-severe AD (ROCKET-ASCEND)
NCT05882877· Phase 3· Amgen Inc.· Source
Active, not recruiting
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
NCT06045806· Phase 3· Celgene· Source
Completed
Digital Tool Enhancing GPs' Information Management for Patients with Multimorbidity - a Pilot Study
NCT06061172· Universitätsklinikum Hamburg-Eppendorf· Source
Completed
A Study Evaluating Pharmacokinetic Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Stage III and Stage IV Melanoma in the Adjuvant Setting
2022-502620-49-00· Phase 1· Amgen Inc.· Source
Completed
Clinical trial of MK-7648A in adults and children with skin cancer
NCT05665595· Phase 3· Merck Sharp & Dohme LLC· Source
Completed
Phase 2 Study of Preoperative Gemcitabine Plus Cisplatin with Durvalumab (MEDI4736) and Tremelimumab in intrahepatic cholangiocarcinoma (NeoTreme)
2024-515660-31-00· Phase 2· Universitaetsklinikum Schleswig-Holstein AöR· Source
Terminated
Hidradenitis Suppurativa Study of Izokibep
NCT05905783· Phase 3· ACELYRIN Inc.· Source
Completed
A 24-month study evaluating physical activity and joint health in patients 12 years and older, with severe haemophilia A treated once weekly with efanesoctocog alfa.
2022-500275-31-00· Phase 3· Swedish Orphan Biovitrum AB (publ)· Source
Completed
A Study to Test the Efficacy and Safety of SAR442970 in Adults With Hidradenitis Suppurativa
NCT05849922· Phase 2· Sanofi· Source
Completed
Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma
NCT05804032· Phase 3· University of Heidelberg Medical Center· Source
Completed
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome
NCT05754957· Phase 3· Janssen Research & Development, LLC· Source
Completed
A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Patients with Previously Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
2023-505816-39-00· Phase 2· F. Hoffmann-La Roche AG· Source
Completed
Vamikibart in Participants With Uveitic Macular Edema
NCT05642325· Phase 3· Hoffmann-La Roche· Source

Showing 50 of 170.

Registry name variants (88)

Trial registries list this institution under these names. Each row is one registry entry: its address and the trials registered under it.

University Medical Center Hamburg-Eppendorf
Hamburg, 20246
473 trials
Universitätsklinikum Hamburg-Eppendorf
Hamburg, 20246
77 trials
Universitaetsklinikum Hamburg-Eppendorf
Hamburg, 20246
30 trials
Universitatsklinikum Hamburg-Eppendorf (UKE)
Hamburg, 20246
7 trials
Department of Neurology, University Medical Center Hamburg-Eppendorf
Hamburg, 20246
2 trials
- NCT06809959Bifocal Transcranial Alternating Current Stimulation Targeting the Frontoparietal Network in Stroke Patients
- NCT07014384Cerebellar Transcranial Direct Current Stimulation (tDCS) in Patients With Isolated Cervical Dystonia (CD)
Hamburg University Medical Centre Eppendorf
Hamburg, Free and Hanseatic City of Hamburg 20251
2 trials
- NCT07114458Delirium and Cognitive Impairment Development in Hospitalized Older Adults Under Isolation Conditions
  Contact: Schrum Silke, Dr
- NCT04978870Diagnosis, Incidence and Consequences of PACU-Delirium
Universitaetsklinikum Hamburg-Eppendorf (UKE)
Hamburg, 20246
2 trials
- NCT04794699Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion
- NCT02975934A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency
Universitätsklinikum Hamburg-Eppendorf, Zentrum für Onkologie
Hamburg, 20246
2 trials
- NCT05804032Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma
- NCT03580655(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis
University Medical Center Hamburg-Eppendorf (UKE)
Hamburg, 20246
2 trials
- NCT02625480Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
- NCT03356392German Stroke Registry - Endovascular Treatment
  Contact: Maximilian Schell
• Department of Anesthesiology, Center of Anesthesiology and Intensive Care Medicine, University Medical Center Hamburg-Eppendorf, Hamburg
Hamburg
1 trial
- NCT07713121Maintaining Intraoperative Mean Arterial Pressure at 85 mmHg or Higher to Reduce Postoperative Delirium in Older Patients With Arterial Hypertension Having Non-cardiac Surgery
  Contact: Karim Kouz, MD
Department of Anesthesiology, University Medical Center Hamburg-Eppendorf
Hamburg, 20246
1 trial
- NCT04978558NIRS vs TCD for Cerebrovascular Autoregulation During Non-cardiac Surgery
Department of Cardiology, University Medical Center Hamburg-Eppendorf
Hamburg, 20246
1 trial
- NCT05442970Cohort Study for Atrial Fibrillation Risk Stratification
  Contact: Renate B Schnabel, Prof.
Department of General-, Visceral- and Thoracic Surgery, University Medical Center Hamburg-Eppendorf
Hamburg, Free and Hanseatic City of Hamburg 20246
1 trial
- NCT06111105GUIDE.MRD-01-CRC: Clinical Validation and Benchmarking of Top Performing ctDNA Diagnostics - Colorectal Cancer
  Contact: Thilo Hackert, MD, MBA
Department of Ophthalmology, University Medical Center Hamburg-Eppendorf
Hamburg, 20246
1 trial
- NCT07531927Safety and Clinical Applicability of Transcorneal Electrical Stimulation (TES) in Geographic Atrophy
  Contact: Ruth Schippert, PhD
Department of Otorhinolaryngology, University Medical Center Hamburg-Eppendorf,
Hamburg, 20246
1 trial
- NCT06019130Nivolumab in Children and Adults With Nasopharyngeal Carcinoma
  Contact: Henrike Zech, MD
Department of Urology, University Medical Center Hamburg-Eppendorf (UKE)
Hamburg
1 trial
- NCT07144319Exploration of Novel AI-enabled Blue Light Enhanced Cystoscopy
  Contact: Victor Schüttfort, MD
Division of Infectious Diseases, I. Department of Internal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
Hamburg, 20246
1 trial
- NCT07125274Sputum-free Diagnostis of TB
  Contact: Thomas Theo Brehm, Dr. med.
Institute for Health Services Research in Dermatology and Nursing, IVDP; University Medical Center Hamburg-Eppendorf,UKE
Hamburg, 20246
1 trial
- NCT07904546ADBest TREAT Registry
  Contact: Matthias Augustin, Prof.Dr.
Institut für Systemische Neurowissenschaften, Universitätsklinikum Hamburg-Eppendorf
Hamburg, 20357
1 trial
- NCT04503083BIOmarkers of MIGraine: a Proof of Concept Study Based on the Stratification of Responders to CGRP Monoclonal Antibodies
The University Medical Center Hamburg-Eppendorf
Hamburg, 20251
1 trial
- NCT06761365LUMENS-1 EU EFS CIP
  Contact: Fabian Flottmann (principal investigator)
Universitaetsklinikum Hamburg-Eppendorf /ID# 154089
Hamburg, 20246
1 trial
- NCT03047395A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS )
Universitaetsklinikum Hamburg-Eppendorf /ID# 222464
Hamburg, 20246
1 trial
- NCT03982394Observational Study of Patients With Moderate to Severe Chronic Plaque Psoriasis
Universitaetsklinikum Hamburg-Eppendorf /ID# 240873
Hamburg, 20246
1 trial
- NCT05139602A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy
Universitaetsklinikum Hamburg-Eppendorf /ID# 249547
Hamburg, 20246
1 trial
- NCT05601882A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
Universitaetsklinikum Hamburg-Eppendorf /ID# 254340
Hamburg, 20246
1 trial
- NCT05959070An Observational Study to Validate the Cumulative Life Course Impairment (CLCI) Instrument (DermCLCI-p) in Adult Participants With Moderate to Severe Chronic Plaque Psoriasis (PsO)
Universitaetsklinikum Hamburg-Eppendorf /ID# 264566
Hamburg, 20246
1 trial
- NCT05753501Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies
Universitaetsklinikum Hamburg-Eppendorf /ID# 277164
Hamburg, 20246
1 trial
- NCT07039110Study to Assess Change in Quality of Life of Risankizumab Treatment in Adult Participants With Moderate-to-Severe Plaque Psoriasis
  Contact: Julieta Gonzalez Blanco
Universitaetsklinikum Hamburg-Eppendorf (Site 0184)
Hamburg, 20246
1 trial
- NCT03713593Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)
Universitaetsklinikum Hamburg-Eppendorf (Site 0268)
Hamburg, 20246
1 trial
- NCT04003636Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)
Universitaetsklinikum Hamburg-Eppendorf (Site 0282)
Hamburg, 20246
1 trial
- NCT03898180Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)
Universitaetsklinikum Hamburg-Eppendorf (Site 0469)
Hamburg, 20246
1 trial
- NCT03867084Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)
Universitaetsklinikum Hamburg-Eppendorf (Site 1556)
Hamburg, 20246
1 trial
- NCT06008756Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes
Universitaetsklinikum Hamburg-Eppendorf (Site 2060)
Hamburg, 20251
1 trial
- NCT06961006A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)
Universitaetsklinikum Hamburg-Eppendorf (UKE) - Ambulanzzentrum des UKE GmbH
Hamburg, 20246
1 trial
- NCT05774756A Trial of Setmelanotide in Acquired Hypothalamic Obesity
Universitaetsklinikum Hamburg-Eppendorf (UKE) /ID# 153056
Hamburg, 20246
1 trial
- NCT02993523A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy
Universitaetsklinikum Hamburg- Eppendorf (UKE) (Site 3010)
Hamburg, 20246
1 trial
- NCT04223791Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018)
Universitaetsklinikum Hamburg- Eppendorf (UKE) (Site 6210)
Hamburg, 20246
1 trial
- NCT04233879Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020)
Universitäres Herzzentrum GmbH, Universitätsklinikum Hamburg-Eppendorf
Hamburg, 20246
1 trial
- NCT01385176Neural Cardiac Therapy for Heart Failure Study (NECTAR-HF)
Universitätsklinikum Hamburg-Eppendorf
Hamburg-Eppendorf
1 trial
- NCT07181291Pulsed Field or Cryoballoon Pulmonary Vein Isolation for Atrial Fibrillation in Heart Failure
Universitätsklinikum Hamburg-Eppendorf - Adults
Hamburg, Free and Hanseatic City of Hamburg 20246
1 trial
- NCT05944016Phase 3 Clinical Trial With Dapagliflozin in Chronic Kidney Disease in Adolescents and Young Adult Patients
  Contact: Markus Gödel, MD
Universitätsklinikum Hamburg-Eppendorf - Children
Hamburg, Free and Hanseatic City of Hamburg 20251
1 trial
- NCT05944016Phase 3 Clinical Trial With Dapagliflozin in Chronic Kidney Disease in Adolescents and Young Adult Patients
  Contact: Jun Oh, MD
Universitätsklinikum Hamburg-Eppendorf, Department of Pediatric Hematology and Oncology, Hubertus Wald Tumor Center, University Cancer Center Hamburg
Hamburg
1 trial
- NCT07647471Evaluation of an Exercise Intervention During Intensive Medical Treatment in Pediatric Oncology.
  Contact: Gabriele Escherich
Universitätsklinikum Hamburg-Eppendorf, Institut und Poliklinik für Allgemeinmedizin
Hamburg, 20246
1 trial
- NCT07476040Improved Management of Patients With Recent-Onset Stable Chest Pain
  Contact: Martin Scherer, Prof. Dr.
Universitätsklinikum Hamburg-Eppendorf, Merz Investigational site #0490079
Hamburg, 20246
1 trial
- NCT03992404Study to Compare the Efficacy and Safety of NT 201 (Botulinum Toxin) With Placebo for the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury
Universitätsklinikum Hamburg-Eppendorf, Neurologie
Hamburg, 20246
1 trial
- NCT05262699Crossmodal Learning in Therapeutic Processes (Task 2-1)
Universitatsklinikum Hamburg-Eppendorf (Site 1212)
Hamburg, 20251
1 trial
- NCT03635567Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)
Universitätsklinikum Hamburg-Eppendorf (UKE), Augenklinik
Hamburg, 20251
1 trial
- NCT04676854Restoration of Central Vision With the PRIMA System in Patients With Atrophic AMD
Universitätsklinikum Hamburg-Eppendorf (UKE), Institut für Versorgungsforschung in der Dermatologie und bei Pflegeberufen (IVDP)
Hamburg, 20246
1 trial
- NCT06324695Development and EValuation of an Online Intervention to Reduce Self-Stigma in People With Visible Chronic Skin disEases
Universitätsklinikum Hamburg-Eppendorf - Zentrum für Onkologie, Studienzentrale Pneumologie
Hamburg, 20246
1 trial
- NCT06317805Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I Patients
University Medical Center Hamburg-Eppendorf, Department of Gynecology
Hamburg, 20246
1 trial
- NCT06489795German-funded Laparoscopic Approach to Cervical Cancer
  Contact: Jan Dieckmann, Dr.
University Medical Center Hamburg-Eppendorf, Dept. of Neurology
Hamburg, Free and Hanseatic City of Hamburg 20246
1 trial
- NCT05560724Network Properties As Biomarkers for Non-Invasive Brain Stimulation (NIBS) After Stroke
  Contact: Robert Schulz, PD Dr. med.
University Medical Center Hamburg-Eppendorf, Institute of Clinical Pharmacology and Toxicology
Hamburg, 20246
1 trial
- NCT06265623Intermittent Hypoxemia, Lung Function Decline, Morbidity, and Mortality in COPD (PROSA Study).
  Contact: Rainer Böger, MD
University Medical Center Hamburg-Eppendorf - (Recruiting only for part 1B and part 2)
Hamburg, 20246
1 trial
- NCT04101357Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411
University Medical Center Hamburg-Eppendorf (UKE), University Heart and Vascular Center Hamburg
Hamburg, Free and Hanseatic City of Hamburg 20249
1 trial
- NCT07794306Balloon- Versus Self-Expanding Intraannular TAVI in Small Aortic Annuli
  Contact: Andreas Schaefer, PD Dr. med.
University Medical Centre Hamburg-Eppendorf
Hamburg-Eppendorf, 20246
1 trial
- NCT06717919HOPE Against Cancer Recurrence in HCC
  Contact: Uta Herden, Prof. Dr.
University of Hamburg, Universitätsklinikum Hamburg-Eppendorf Hamburg, Department of Psychiatry and Psychotherapy
Hamburg, Free and Hanseatic City of Hamburg 20246
1 trial
- NCT07645443FEEL-GOOD: A Multicenter Trial of a Mindfulness-Based Group Therapy in Young Adults With Early Psychosis
  Contact: Schirin Gellert
UKE, Universitatsklinikum Hamburg-Eppendorf
Hamburg, 20246
Universitaetsklinikum Hamburg-Eppendorf /ID# 215495
Hamburg, 20246
Universitaetsklinikum Hamburg-Eppendorf /ID# 239636
Hamburg, 20246
Universitaetsklinikum Hamburg-Eppendorf /ID# 239658
Hamburg, 20246
Universitaetsklinikum Hamburg-Eppendorf /ID# 243141
Hamburg, 20246
Universitaetsklinikum Hamburg-Eppendorf /ID# 257782
Hamburg, 20246
Universitaetsklinikum Hamburg-Eppendorf /ID# 258617
Hamburg, 20246
Universitaetsklinikum Hamburg-Eppendorf /ID# 260444
Hamburg, 20246
Universitaetsklinikum Hamburg-Eppendorf /ID# 260651
Hamburg, 20246
Universitaetsklinikum Hamburg-Eppendorf /ID# 262493
Hamburg, 20246
Universitaetsklinikum Hamburg-Eppendorf /ID# 263730
Hamburg, 20246
Universitaetsklinikum Hamburg-Eppendorf /ID# 264280
Hamburg, 20246
Universitaetsklinikum Hamburg-Eppendorf /ID# 269429
Hamburg, 20246
Universitaetsklinikum Hamburg-Eppendorf /ID# 275803
Hamburg, 20246
Universitaetsklinikum Hamburg-Eppendorf /ID# 276869
Hamburg, 20246
Universitaetsklinikum Hamburg-Eppendorf (Ph3)
Hamburg, 20246
Universitaetsklinikum Hamburg Eppendorf (Site 0407)
Hamburg, 20246
Universitaetsklinikum Hamburg-Eppendorf (Site 0445)
Hamburg, 20246
Universitaetsklinikum Hamburg-Eppendorf (Site 0524)
Hamburg, 20246
Universitaetsklinikum Hamburg-Eppendorf (Site 0610)
Hamburg, 20246
Universitaetsklinikum Hamburg-Eppendorf (Site 1007)
Hamburg, 20246
Universitaetsklinikum Hamburg-Eppendorf (Site 1214)
Hamburg, 20246
Universitaetsklinikum Hamburg-Eppendorf (Site 1309)
Hamburg, 20246
Universitaetsklinikum Hamburg-Eppendorf (Site 2118)
Hamburg, 20246
Universitaetsklinikum Hamburg-Eppendorf (UKE) /ID# 207982
Hamburg, 20246
Universitaetsklinikum Hamburg Eppendorf (UKE) (Site 0352)
Hamburg, 20246
Universitaetsklinikum Hamburg-Eppendorf (UKE) - Universitaeres Cancer Center Hamburg (UCCH)
Hamburg
Universitätsklinikum Hamburg-Eppendorf - Hauttumorzentrum
Hamburg, 20246
Universitätsklinikum Hamburg Eppendorf - II. Med.
Hamburg, 20246
Universitätsklinikum Hamburg-Eppendorf, Psychiatrie
Hamburg, 20246
Universitätsklinikum Hamburg-Eppendorf - University Medical Center Hamburg-Eppendorf
Hamburg, 20246
Universitätsklinikum Hamburg Eppendorf, Zentrum für Kinder- und Jugendmedizin, Abt. Pädiatrische Hämatologie und Onkologie
Hamburg, 20246

Conditions

Diseases this institution publishes on or runs trials for.

Stroke226 works · 37 trials
Prostate cancer118 works · 33 trials
Heart failure114 works · 18 trials
Atrial fibrillation101 works · 14 trials
Melanoma69 works · 30 trials
Multiple myeloma67 works · 54 trials
Bladder cancer57 works · 9 trials
Chronic kidney disease49 works · 9 trials
Aortic aneurysm37 works · 5 trials
Glioblastoma35 works · 5 trials
Ovarian cancer32 works · 16 trials
Kidney cancer31 works · 9 trials
Osteoporosis31 works · 1 trial
Psoriasis30 works · 9 trials
Sarcoma29 works · 10 trials
Atopic dermatitis (eczema)27 works · 12 trials
Nephrotic syndrome21 works · 1 trial
Metastatic breast cancer20 works · 10 trials
Brain aneurysm19 works · 4 trials
Neuroendocrine tumours19 works · 2 trials
Brain metastases19 works · 0 trials
Neurofibromatosis type 117 works · 4 trials
Acute lymphoblastic leukaemia16 works · 21 trials
Macular degeneration12 works · 12 trials
Meningioma11 works · 0 trials
Mesothelioma10 works · 0 trials
Ventricular tachycardia9 works · 0 trials
Myelodysplastic syndromes9 works · 7 trials
Myasthenia gravis9 works · 4 trials
Myeloproliferative neoplasms9 works · 10 trials

Institution data: ROR 01zgy1s35 (CC0-1.0)Updated 14 Nov 2026

Report an error